Ultragenyx Cuts 130 Jobs After Setrusumab Fails; VERAXA Shareholders OK Financing Changes
Ultragenyx cuts 10% of staff after setrusumab Phase III misses; VERAXA Biotech shareholders approve capital and board changes at EGM.
Ultragenyx Pharmaceutical Inc
CompanyAlso known as: Ultragenyx, Ultragenyx Pharmaceutical
Company Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company focused on developing therapies for rare and ultra-rare genetic diseases. Founded in 2010 and headquartered in Novato, California, it trades on Nasdaq under RARE.
- Website
- https://www.ultragenyx.com
- Headquarters
- Novato, California, USA
- Founded
- 2010
- Stock Ticker
- NASDAQ:RARE
Related News
Ultragenyx Reports Multiple 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx granted 65,886 RSUs to 39 new non-executive officers in July 2026 and reported similar inducement grants in April, May, and June 2026. Awards vest over four years.
Two Securities Class Action Lawsuits Filed Against Biopharmaceutical Companies Over Alleged Clinical Trial Misstatements
Two securities class action lawsuits have been filed against NASDAQ-listed biopharmaceutical companies Ultragenyx and Vistagen. Both cases allege defendants made misleading statements about clinical trial results for key drug programs. Investors face deadlines in March and April 2026 to request lead plaintiff status.
Ultragenyx launches restructuring plan as class action targets setrusumab disclosures
Ultragenyx began a restructuring plan that includes a 10% workforce reduction and termination of UX143 manufacturing agreements. The company also faces a class action tied to setrusumab disclosures.
FDA Clears Ultragenyx UX016 for GNE Myopathy; Soligenix Advances HyBryte in CTCL
Ultragenyx received FDA clearance for UX016 in GNE myopathy, with a Phase 1/2 study planned for 2026. Soligenix's confirmatory HyBryte trial for CTCL has 66 of 80 patients enrolled, and an interim analysis is expected in early 2026.
Class Action Lawsuits Filed Against Atara, Ultragenyx, Mereo, and Vistagen Over Alleged Misstatements
Class action lawsuits allege false statements about clinical trial results and regulatory prospects at Atara Biotherapeutics, Ultragenyx, Mereo BioPharma, and Vistagen Therapeutics. The complaints cite failed Phase 3 studies for setrusumab in Osteogenesis Imperfecta and fasedienol for social anxiety disorder, along with manufacturing issues affecting Atara's tabelecleucel application. Investors have deadlines ranging from April to May 2026 to seek lead plaintiff status.
Analysts Update Ratings on Healthcare Stocks: Ultragenyx Strong Buy, Immutep Downgraded
Analysts updated ratings on healthcare stocks: Ultragenyx remains Strong Buy, Immutep downgraded to Hold, BridgeBio gets Buy. American Well and Baxter stay Hold. Upside ranges from 11% to 154%.
Opus Genetics Reports Progress in Gene Therapy Pipeline; Ultragenyx Announces Restructuring
Opus Genetics reported positive early data from its BEST1 gene therapy program and expects FDA action on its presbyopia treatment in October 2026. Ultragenyx announced 2025 revenue of $673 million and initiated a strategic restructuring plan targeting profitability in 2027.
Ultragenyx Receives FDA Priority Review for DTX401 Gene Therapy for GSD Type Ia
The FDA has accepted Ultragenyx's BLA for DTX401, an AAV gene therapy for Glycogen Storage Disease Type Ia, granting Priority Review with a PDUFA action date of August 23, 2026.
Ultragenyx Faces Lawsuits Over Trial Data as UX111 Gene Therapy Advances
Ultragenyx Pharmaceutical confronts multiple shareholder class action lawsuits over Phase III trial disclosures while reporting positive UX111 gene therapy data and implementing a 10% workforce reduction.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07511556 |
First-in-human Study of UX016 in GNEM |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07447648 |
Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) |
RECRUITING | |
| NCT07159581 |
Gene Therapy for Wilson Disease Evaluated by 64Cu PET/CT |
ENROLLING_BY_INVITATION | |
| NCT07157254 |
A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS) |
RECRUITING | PHASE2 |
| NCT07097311 |
Study to Evaluate the Use of Triheptanoin in Patients With Medium Chain Acyl-CoA Dehydrogenase Deficiency (MCADD) |
WITHDRAWN | PHASE2 |
| NCT06636383 |
Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program |
RECRUITING | |
| NCT06636071 |
Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06617429 |
Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS) |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06415344 |
Long-term Extension of GTX-102 in Angelman Syndrome |
ENROLLING_BY_INVITATION | PHASE3 |
| NCT06340685 |
Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency |
RECRUITING | PHASE1 |